Source: AP Images

In an­oth­er blow to In­ter­cept, the FDA is in­ves­ti­gat­ing Ocali­va for po­ten­tial risk of liv­er dis­or­der

Just a month be­fore hand­ing In­ter­cept Phar­ma­ceu­ti­cals a CRL for Ocali­va in NASH, the FDA be­gan eval­u­at­ing the drug for a po­ten­tial risk of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.